Neurologic, BP Meds May Lower Risk of Breast Tumour Development
Researchers have found that combining neurologic and blood pressure drugs may reduce breast tumour development.
According to the study, published in the journal Scientific Reports, adding a medication used to treat epilepsy, bipolar disorder and migraines to a blood pressure medicine reversed some aspects of breast cancer in the offspring of mice at high risk of the disease because of the high-fat diet-fed to their mothers during pregnancy.
"This finding may have important implications in people because exposures in the womb to certain chemicals, or a mother's high-fat diet, or being obese, can subsequently increase a daughter's breast cancer risk," Hilakivi-Clarke.
According to the researchers, the key drug in the study regimen was valproic acid which, among several targets, inhibits histone deacetylase (HDAC), an important epigenetic silencer of genes.
In contrast to mutations that permanently disrupt the normal functions of genes, epigenetic modifications are reversible.
Early treatment studies in people have shown that these two drugs can work in tandem to disrupt tumour growth.
These research findings demonstrate how impactful an epigenetic methyl group addition or subtraction from DNA can be.
Compounds that reduce methylation of tumour suppressor genes that are excessively methylated (hypermethylated) can be beneficial.
However, these drugs can have the opposite effect if tumour suppressor genes are not hypermethylated; they may remove methyl groups from cancer-causing genes, making these genes more active and potentially leading to more aggressive cancers.
Some compounds in these foods, especially folic acid, have opposite effects.
This research suggests that exposure to a high-fat diet or endocrine-disrupting chemicals in the womb might be reversed by the consumption of foods high in DNMT and HDAC inhibitors, while those who have not had such exposures might also gain a cancer-protective benefit from consuming foods high in folic acid.
The scientists noted, however, that their findings, particularly as they relate to diet, need to be studied in people.
"Our next step will be to try to identify biomarkers in humans that indicate exposure in the womb to diets or endocrine-disrupting chemicals that could increase breast cancer risk later in life," said Hilakivi-Clarke.
(Make sure you don't miss fresh news updates from us. Click here to stay updated)